Your browser is no longer supported. Please, upgrade your browser.
Settings
BLCM Bellicum Pharmaceuticals, Inc. daily Stock Chart
BLCM [NASD]
Bellicum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own0.40% Shs Outstand43.36M Perf Week-1.68%
Market Cap177.78M Forward P/E- EPS next Y-2.27 Insider Trans-21.04% Shs Float31.62M Perf Month-20.85%
Income-92.70M PEG- EPS next Q-0.56 Inst Own57.60% Short Float8.11% Perf Quarter-39.17%
Sales0.70M P/S253.97 EPS this Y-12.60% Inst Trans-5.08% Short Ratio6.97 Perf Half Y-47.97%
Book/sh2.13 P/B1.92 EPS next Y3.80% ROA- Target Price19.00 Perf Year-59.00%
Cash/sh2.60 P/C1.58 EPS next 5Y- ROE- 52W Range3.92 - 10.40 Perf YTD-51.25%
Dividend- P/FCF- EPS past 5Y-18.20% ROI-74.50% 52W High-60.58% Beta1.03
Dividend %- Quick Ratio8.00 Sales past 5Y-33.90% Gross Margin54.80% 52W Low4.59% ATR0.32
Employees137 Current Ratio8.00 Sales Q/Q200.00% Oper. Margin- RSI (14)35.92 Volatility6.49% 7.97%
OptionableYes Debt/Eq0.39 EPS Q/Q22.20% Profit Margin- Rel Volume0.65 Prev Close4.29
ShortableYes LT Debt/Eq0.39 EarningsNov 06 Payout- Avg Volume368.24K Price4.10
Recom1.30 SMA20-6.50% SMA50-23.01% SMA200-40.02% Volume240,835 Change-4.43%
Apr-12-18Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17Initiated Wells Fargo Outperform
Dec-01-16Initiated Raymond James Outperform
Nov-30-16Initiated Ladenburg Thalmann Buy
Nov-02-16Initiated Cantor Fitzgerald Buy $32
Aug-09-16Upgrade Citigroup Neutral → Buy
Feb-25-16Initiated Citigroup Neutral $11
Sep-11-15Upgrade Guggenheim Neutral → Buy
Jul-24-15Initiated Citigroup Buy
Nov-07-18 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-06-18 06:00PM  Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 09:01AM  Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting GlobeNewswire +8.35%
Oct-17-18 08:30AM  Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-23-18 08:15AM  Factors of Influence in 2018, Key Indicators and Opportunity within Qurate Retail Group, Bellicum Pharmaceuticals, CannTrust, Iconix Brand Group, Maxwell Technologies, and AZUL SA New Research Emphasizes Economic Growth GlobeNewswire
Aug-20-18 11:45PM  Edited Transcript of BLCM earnings conference call or presentation 7-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-07-18 07:50PM  Bellicum Pharmaceuticals (BLCM) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
03:00PM  Bellicum Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-06-18 07:00AM  Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501 GlobeNewswire
Aug-04-18 01:04PM  Here's Why Bellicum Pharmaceuticals Lost 13.8% in July Motley Fool
Jul-31-18 07:00AM  Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 GlobeNewswire
Jul-24-18 07:30AM  Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE
Jul-16-18 04:25PM  Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer GlobeNewswire
Jun-25-18 07:15AM  Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-15-18 07:45AM  Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and BioDelivery Sciences International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-12-18 08:20AM  Today's Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Sangamo Therapeutics ACCESSWIRE
May-30-18 07:00AM  Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-29-18 07:00AM  Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel GlobeNewswire
May-17-18 09:20AM  Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association GlobeNewswire
May-15-18 07:00AM  Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
May-10-18 08:20AM  Todays Research Reports on Stocks to Watch: OPKO Health and Bellicum Pharmaceuticals ACCESSWIRE
May-09-18 01:57PM  Here's Why Bellicum Pharmaceuticals Is Jumping Higher Today Motley Fool +15.60%
May-08-18 04:01PM  Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-20-18 04:05PM  Bellicum Pharmaceuticals Announces Closing of Public Offering GlobeNewswire
Apr-17-18 06:26PM  Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.60%
02:33PM  Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today Motley Fool
Apr-16-18 04:42PM  Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-12-18 09:47AM  Is Bellicum Pharmaceuticals Stock Now a Strong Buy? Motley Fool +20.29%
08:30AM  Todays Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals ACCESSWIRE
07:51AM  What Do Analysts Think About Bellicum Pharmaceuticals Incs (NASDAQ:BLCM) Long Term Outlook? Simply Wall St.
Apr-11-18 04:17PM  Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 GlobeNewswire
Apr-09-18 11:10AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm ACCESSWIRE
10:11AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline: April 9, 2018 ACCESSWIRE
Apr-04-18 09:42PM  APRIL 9 DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm ACCESSWIRE
Apr-03-18 02:25PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
Apr-01-18 06:00AM  FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact The Firm GlobeNewswire
Mar-29-18 03:00PM  DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
Mar-26-18 05:31PM  BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm Business Wire
Mar-21-18 04:03PM  BLCM NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. - BLCM PR Newswire
Mar-20-18 02:51PM  Lifshitz & Miller LLP Announces Investigation of Atlas Financial Holdings, Inc., Bellicum Pharmaceuticals, Inc., Celgene Corporation, Foot Locker, Inc., Kraton Corporation, Riot Blockchain, Inc., and Ulta Beauty, Inc. PR Newswire
Mar-19-18 10:06AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline: April 9, 2018 ACCESSWIRE
Mar-17-18 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline BLCM Business Wire
Mar-16-18 03:49PM  BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Bellicum Pharmaceuticals, Inc. To Contact The Firm PR Newswire
Mar-15-18 07:30AM  Blog Exposure - Bellicum Reported Encouraging Interim Data in Pediatric AML Patients Treated with BPX-501 ACCESSWIRE
Mar-14-18 07:26PM  Edited Transcript of BLCM earnings conference call or presentation 13-Mar-18 9:00pm GMT Thomson Reuters StreetEvents
04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BLCM ACCESSWIRE
01:47PM  Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Bellicum Pharmaceuticals, Inc. Business Wire
10:49AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline: April 9, 2018 ACCESSWIRE
Mar-13-18 04:01PM  Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 GlobeNewswire
02:14PM  DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact the Firm Business Wire
12:30PM  Bellicum Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
09:10AM  Where Bellicum Pharmaceuticals Incs (NASDAQ:BLCM) Earnings Growth Stands Against Its Industry Simply Wall St.
07:54AM  Bellicum Pharmaceuticals Earnings Outlook Benzinga
07:00AM  Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 GlobeNewswire
Mar-11-18 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline BLCM Business Wire
Mar-09-18 04:14PM  BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm GlobeNewswire
Mar-08-18 04:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BLCM ACCESSWIRE
01:15PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
Mar-06-18 07:00AM  Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018 GlobeNewswire
Mar-05-18 12:54PM  EQUITY NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. BLCM GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) and Lead Plaintiff Deadline April 9, 2018 GlobeNewswire
Mar-03-18 06:56AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BLCM ACCESSWIRE
Mar-02-18 11:25PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit GlobeNewswire +7.83%
Mar-01-18 10:32AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018 ACCESSWIRE
08:14AM  Bellicum (BLCM) Alert: Johnson Fistel Announces Filing of Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.; Encourages Investors to Contact the Firm PR Newswire
Feb-28-18 04:30PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE -5.05%
Feb-27-18 06:02PM  BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Bellicum Pharmaceuticals, Inc. to Contact the Firm Business Wire
07:40AM  Wired News Bellicum Pharma Shares Update On Clinical Hold of BPX-501 Studies in the US ACCESSWIRE
Feb-24-18 08:10AM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers BLCM GlobeNewswire
Feb-23-18 11:05AM  BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm Business Wire +5.40%
10:37AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018 ACCESSWIRE
07:00AM  Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies GlobeNewswire
Feb-22-18 03:15PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE
Feb-21-18 07:00AM  Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors GlobeNewswire
Feb-20-18 05:42PM  IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc. GlobeNewswire
02:50PM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit Business Wire
Feb-17-18 11:20AM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
08:00AM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM PR Newswire
Feb-15-18 04:12PM  BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action BLCM Business Wire
Feb-14-18 07:15PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE
Feb-13-18 06:24PM  BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:46AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM ACCESSWIRE
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline April 9, 2018 GlobeNewswire
Feb-12-18 03:17PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. GlobeNewswire
Feb-10-18 09:07AM  Is Bellicum Pharmaceuticals, Inc. a Buy Now? Motley Fool
Feb-09-18 04:50PM  Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM ACCESSWIRE
12:36PM  Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action Business Wire
08:30AM  Todays Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics ACCESSWIRE
Feb-08-18 03:35PM  Ongoing Investigation: The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE -10.58%
02:45PM  Here's how Triad stocks fared this week American City Business Journals
01:31PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
Feb-07-18 07:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bellicum Pharmaceuticals, Inc. (BLCM) GlobeNewswire +10.66%
12:20PM  The Schall Law Firm Announces An Ongoing Investigating of Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018 PR Newswire
Feb-06-18 10:18PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bellicum Pharmaceuticals, Inc. ACCESSWIRE
03:33PM  Here are the U.S. stocks getting pummeled in the market rout American City Business Journals
03:21PM  Here are the D.C.-area stocks getting pummeled in the market rout American City Business Journals
03:13PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. BLCM Business Wire
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-701, a T cell receptors (TCR) based therapy in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma; and CD19, a chimeric antigen receptor T cell therapy for expressing B cell malignancies setting. It has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T cell therapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stonehouse Jon PDirectorNov 09Buy4.5610,00045,60010,000Nov 13 04:01 PM
Spencer David M.Chief Technology OfficerSep 04Sale7.0410,00070,41389,939Sep 05 04:02 PM
Spencer David M.Chief Technology OfficerJul 18Sale7.6340,000305,13299,939Jul 20 04:01 PM
Musso Alan ACFO and TreasurerMay 25Sale7.976,20649,46626,548May 29 04:49 PM
BAKER BROS. ADVISORS LP10% OwnerJan 19Sale7.91295,3612,336,21758,131Jan 19 04:57 PM
BAKER BROS. ADVISORS LP10% OwnerJan 18Sale8.12324,7742,635,76862,267Jan 19 04:57 PM
BAKER BROS. ADVISORS LP10% OwnerJan 17Sale8.63260,6002,247,91066,815Jan 19 04:57 PM
Smith Alan K.EVP, Technical OperationsJan 09Sale9.404874,5782,087Jan 11 04:02 PM
Musso Alan ACFO and TreasurerDec 11Sale9.3317,117159,66731,585Dec 13 04:05 PM